Bruce Thompson, Ph.D.

Bruce Thompson, Ph.D.

President and Chief Technology Officer
Kincell Bio
Bruce Thompson brings more than 28 years of experience to his position as President and Chief Technology Officer. Bruce is the Founding CEO of Kincell, where he built the technical and operations teams and launched Kincell’s tech-savvy CDMO offerings to market. Before his role with Kincell, Bruce was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped to build the development and GMP manufacturing capabilities and served as a technical advisor.

Bruce has over 18 years of experience in CMC strategy, product development, and cell therapy manufacturing. As Vice President of Process Sciences at Lyell Immunopharma, he was responsible for Process and Analytical Development, as well as tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Before Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He supported more than 15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs. Bruce also spent nearly 10 years at Pfizer in the Pharmaceutical Sciences division, where he gained expertise in analytical and process development.

Bruce received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University, and a Ph.D. in Microbiology and Immunology from the University of Louisville.

Articles by Bruce Thompson, Ph.D.

  • Narrowing the CGT access gap

    Tuesday, January 27, 2026
    There is significant opportunity to expand the applications of cell therapy further into rare diseases as well as to tackle widespread conditions.

  • Beyond CAR-T: Building manufacturing strategies for the next generation of regenerative cell therapies

    Monday, July 27, 2026
    As cell and gene therapy shifts toward in vivo approaches and regenerative modalities — iPSCs, MSCs, HSCs, and beyond — sponsors face new challenges beyond traditional CAR-T manufacturing: bioreactor and culture system selection, analytical strategy, and potency assay development for cell types with far less manufacturing precedent.